• Johnson & Johnson announced new Phase 2 nipocalimab findings identifying mouth dryness as the symptom Sjögren's disease patients most wanted improved.
• The patient-experience findings will be presented at the American College of Rheumatology Convergence 2026.
• Previously reported Phase 2 results showed improved saliva production versus placebo, with reduced disease activity and severity.
• Two Phase 3 studies are ongoing, incorporating measures of symptoms and outcomes important to patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611071003PR_NEWS_USPR_____NY88407) on November 07, 2026, and is solely responsible for the information contained therein.